{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:07:49Z","timestamp":1792786069419,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["CFH, 2020-1-1071"],"award-info":[{"award-number":["CFH, 2020-1-1071"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognosis of patients with recurrent WHO grade 4 glioma is poor, particularly in glioblastoma, which has a median survival of approximately 6 months and no effective treatment options. We evaluated the short-term (28-day) safety and efficacy of ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in patients with recurrent WHO grade 4 glioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-arm, phase 1\/2 clinical trial, eligible patients received intratumoral injections of ON-01 under stereotactic guidance. The primary endpoint was to assess the short-term safety profile of ON-01 treatment. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and the 2-year OS rate. An exploratory objective was to identify tumor-related biomarkers predictive of treatment efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 30 patients treated with ON-01, 13 (43.3%) were male, and the median age was 50.0 years (range, 22-75). A total of 36 grade 1, 12 grade 2, and 2 grade 3 adverse events were reported. Among all treated patients, the median OS was 12.0 months (95% CI, 10.1-13.9), median PFS was 3.0 months (95% CI, 1.7-4.3), and 2-year OS rate was 27.7% (95% CI, 12.6%-45.0%). Seven patients with recurrent multifocal gliomas demonstrated regression of non-injection site lesions following ON-01 therapy. Furthermore, patients with elevated expression of herpesvirus entry mediator exhibited significantly prolonged survival (P\u2009=\u2009.015).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intratumoral infusion of ON-01 appeared safe and demonstrated efficacy in patients with recurrent malignant glioma, with no evidence of neurotoxicity. The therapeutic response to ON-01 may be associated with HVEM expression levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag005","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:48:53Z","timestamp":1767962933000},"page":"1239-1250","source":"Crossref","is-referenced-by-count":4,"title":["ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: A single-arm, phase 1\/2 study"],"prefix":"10.1093","volume":"28","author":[{"given":"Wei","family":"Zeng","sequence":"first","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Capital Medical University Electric Power Teaching Hospital\/State Grid Beijing Electric Power Hospital , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Fang","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Capital Medical University Electric Power Teaching Hospital\/State Grid Beijing Electric Power Hospital , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Capital Medical University Electric Power Teaching Hospital\/State Grid Beijing Electric Power Hospital , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Qin","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Gao","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Su","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqiang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankun","family":"Wu","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yida","family":"Liu","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huacong","family":"Lu","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Mu","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Capital Medical University Electric Power Teaching Hospital\/State Grid Beijing Electric Power Hospital , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guishan","family":"Jin","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangang","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Functional Neurosurgery, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University , Beijing, People\u2019s Republic of","place":["China"]},{"name":"Beijing Laboratory of Biomedical Materials , Beijing, People\u2019s Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2026051916123490800_noag005-B1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026051916123490800_noag005-B2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"key":"2026051916123490800_noag005-B3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/annonc\/mdp591","article-title":"Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma","volume":"21","author":"Verhoeff","year":"2010","journal-title":"Ann Oncol"},{"key":"2026051916123490800_noag005-B4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026051916123490800_noag005-B5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA\u00a0Cancer J Clin"},{"key":"2026051916123490800_noag005-B6","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","article-title":"Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma","volume":"12","author":"Lee","year":"2021","journal-title":"Nat Commun"},{"key":"2026051916123490800_noag005-B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment","author":"Arrieta","year":"2023","journal-title":"J Clin Invest"},{"key":"2026051916123490800_noag005-B8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.annonc.2021.03.197","article-title":"Oncolytic virus in gliomas: a review of human clinical investigations","volume":"32","author":"Carpenter","year":"2021","journal-title":"Ann Oncol"},{"key":"2026051916123490800_noag005-B9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"key":"2026051916123490800_noag005-B10","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"31","author":"Todo","year":"2025","journal-title":"Nat Med"},{"key":"2026051916123490800_noag005-B11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"2026051916123490800_noag005-B12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"key":"2026051916123490800_noag005-B13","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u0394 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat Commun"},{"key":"2026051916123490800_noag005-B14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Mol Ther"},{"key":"2026051916123490800_noag005-B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.chom.2006.12.001","article-title":"HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein","volume":"1","author":"Orvedahl","year":"2007","journal-title":"Cell Host Microbe"},{"key":"2026051916123490800_noag005-B16","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msac142","article-title":"Simplexviruses successfully adapt to their host by fine-tuning immune responses","volume":"39","author":"Mozzi","year":"2022","journal-title":"Mol Biol Evol"},{"key":"2026051916123490800_noag005-B17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2020.09.013","article-title":"Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft","volume":"495","author":"Liu","year":"2020","journal-title":"Cancer Lett"},{"key":"2026051916123490800_noag005-B18","doi-asserted-by":"publisher","first-page":"110581","DOI":"10.1016\/j.cellsig.2022.110581","article-title":"Oncolytic HSV-1 suppresses cell invasion through downregulating Sp1 in experimental glioblastoma","volume":"103","author":"Zhang","year":"2023","journal-title":"Cell Signal"},{"key":"2026051916123490800_noag005-B19","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051916123490800_noag005-B20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.chom.2015.01.002","article-title":"RIP1\/RIP3 binding to HSV-1 ICP6 initiates necroptosis to restrict virus propagation in mice","volume":"17","author":"Huang","year":"2015","journal-title":"Cell Host Microbe"},{"key":"2026051916123490800_noag005-B21","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026051916123490800_noag005-B22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/2159-8290.CD-NB2015-158","article-title":"First oncolytic viral therapy for melanoma","volume":"6","author":"Poh","year":"2016","journal-title":"Cancer Discov"},{"key":"2026051916123490800_noag005-B23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2026051916123490800_noag005-B24","doi-asserted-by":"publisher","first-page":"e1011693","DOI":"10.1371\/journal.ppat.1011693","article-title":"Binding of herpesvirus entry mediator (HVEM) and HSV-1 gD affect reactivation but not latency levels","volume":"19","author":"Jaggi","year":"2023","journal-title":"PLoS Pathog"},{"key":"2026051916123490800_noag005-B25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026051916123490800_noag005-B26","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1093\/neuonc\/noae177","article-title":"Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma","volume":"26","author":"Duerinck","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026051916123490800_noag005-B27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1756-9966-28-60","article-title":"The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine","volume":"28","author":"Maschio","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"2026051916123490800_noag005-B28","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026051916123490800_noag005-B29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/neuonc\/nox038","article-title":"Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity","volume":"19","author":"Hiraoka","year":"2017","journal-title":"Neuro Oncol"},{"key":"2026051916123490800_noag005-B30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"2026051916123490800_noag005-B31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11060-016-2157-2","article-title":"Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma","volume":"129","author":"Mandel","year":"2016","journal-title":"J Neurooncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag005\/66382210\/noag005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/5\/1239\/66382210\/noag005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/5\/1239\/66382210\/noag005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:12:42Z","timestamp":1779221562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/5\/1239\/8423499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,12]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag005","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,12]]}}}